Michael Hayden, Founder of Prilenia

Michael Hayden is the founder of Prilenia. Prilenia has raised $85M in total funding. Latest round: Series A. Based in Israel, Netherlands.

About Michael Hayden

Michael Hayden, MD, PhD, is the CEO and founder of Prilenia Therapeutics, a clinical-stage biotechnology company. He leads the company's efforts with its lead asset, pridopidine, which is in Phase 3 trials for Huntington's disease and a Phase 2/3 trial for ALS. Hayden has been with Prilenia since its founding in 2018.

Michael Hayden at a glance

More founders in Israel, Netherlands (44)

Browse related founder lists (6)

Full founder directory · Investor directory · Company funding database · Fundraising library